We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Reliance Gen. | LSE:GMX | London | Ordinary Share | GB00B1MM9925 | ORD 10P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.55 | 0.00 | 00:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 0.55 | GBX |
Reliance Genemedix (GMX) Share Charts1 Year Reliance Genemedix Chart |
|
1 Month Reliance Genemedix Chart |
Intraday Reliance Genemedix Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 07/3/2012 | 09:52 | And the most overvalued stock on the market is ? | 35 |
| 07/3/2012 | 09:51 | GMX- bid or merger | 344 |
| 03/2/2010 | 20:55 | GMX with Charts | 8 |
| 01/6/2007 | 10:12 | I hold and if Directors are correct re. future funding then | 23 |
| 19/2/2004 | 13:57 | The future is bright | 122 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 07/2/2007 16:32 by wiganer Looks a cracking short for anyone who goes in for that kind of thing vols.Compare the current price with the placing price. |
Posted at 25/7/2006 12:31 by jotoha1 Why is this company cap'd @£14million, is it april 1st, on my calc the share price should be 1/2p...any thoughts? |
Posted at 13/10/2005 11:09 by eriktherock ENCOURAGING STUFF!RNS Number:6088S GeneMedix PLC 13 October 2005 FOR IMMEDIATE RELEASE 13 October 2005 GENEMEDIX PLC Sale of Chinese Facility, Convertible Loan Funding GeneMedix plc ("GeneMedix" or "the Company"), the UK biopharmaceutical company with operations in Europe and Asia and with joint London and Singapore Stock Exchange listings, announces that, as part of its recently announced restructuring, it has signed a binding letter of intent for the sale of its Chinese facility and has entered into a related party transaction to bring in additional financing to the business. The £500,000 financing will contribute to the Company's immediate funding requirements, and the sale of the Chinese facility, after payment of all debt, will provide approximately £1.6 million in early 2006. If the Company is to continue to pursue it EPO programme at its current rate, additional financing will be required over the coming months. The Board of Directors plans to access this additional funding from the restructuring process. The Chinese facility has not been part of the Company's core activities for some time and the funding of the sale will occur upon receipt of Chinese government approval. In the financing, GeneMedix placed a convertible loan of £500,000 with its founder and Chairman, Dr Kim Tan. These loan notes are convertible into between 11.8 and 13.1 million shares of the Company's shares when the Company completes its next share offering. To facilitate the financing of this convertible loan, a trust holding certain of Dr Kim Tan's shares in GeneMedix disposed of 18,567,397 GeneMedix shares at a price of 2.8p in a private placing with a non-connected party. Julian Attfield, Acting Chief Executive Officer of GeneMedix commented: "We are delighted that our restructuring efforts have begun in such a positive manner. The cash proceeds from the sale of the Chinese facility will be welcome in meeting our cash requirements in early 2006. We are also grateful to Dr Tan for his continued financial support for the Company which allows us more time to advance the current financing and corporate activities whilst continuing at full speed with our development activities." Notification of these transactions has been made today in accordance with Disclosure Rule 3.1.4R(1)(a) of the Disclosure Rules sourcebook. Following this transaction, Dr Kim Tan has a total actual beneficial interest in 128,786,159 ordinary shares, representing 34.7% of the enlarged share capital of the Company, but this will increase to a maximum of 141,858,054 ordinary shares representing 36.9% of the enlarged share capital of the Company, once the loan notes have been converted. Mr J Attfield, Acting CEO of GeneMedix, is the duly authorised officer of the Company responsible for making the notification. ENQUIRIES: |
Posted at 04/10/2005 08:13 by wiganer GMX left today. Sinking ship, or multi-bagger? |
Posted at 05/3/2005 22:41 by eriktherock by my calculations( provided upon kind request) we are looking at a share price of 22p based on current standing. This is high risk of course. |
Posted at 23/2/2004 13:47 by andyprice5569 Hi Nil Pd,'Now I wonder what would happen if Singapore traders bought their shares here (for two thirds of the price) instead of locally. Seems like we will be moving toward parity soon.' What is 'parity'? Firstly, one has to find out what price GMX opened at on the Singapore stock exchange (the first day of trading); find out what the GMX UK share price was that day; find out what the exchange rates (£ and Singapore $) was on the day GMX opened in Singapore; find out what the exchange rate for the £ and Sing $ is today; find out the difference. Currency fluctuations between the £ and the Sing $ will have had an effect on the price of shares in the UK (you think cheap) compared to the price of shares in Singapore (where you think they are dearer). HTH - Regs, Andy |
Posted at 19/2/2004 13:38 by baker man GeneMedix PLC19 February 2004 GENEMEDIX PLC Statement Re: Share Price Movement GeneMedix plc ('the Company'), the UK biopharmaceutical company with operations in Europe and Asia and with joint London and Singapore Stock Exchange listings, makes the following statement regarding its share price: The Company notes the significant increase in its share price following its announcement on 16 February 2004. The Company wishes to clarify the position in relation to the significant potential transaction referred to in that announcement and its current financial position and prospects. The potential transaction referred to in the announcement of 16 February 2004 is at an early stage of negotiation. For the avoidance of doubt, no outright cash offer for the Company has been proposed and the Directors do not believe that any such offer is being contemplated. The Company announces today that it intends to release its preliminary results for the 12 months ended 30 November 2003 on 26 February 2004. Since the announcement of its interim results for the nine months ended 31 August 2003, in which the Directors highlighted the Company's need to focus on preserving its cash balances, the Company has continued to operate on a cash flow negative basis. In that announcement, the Directors expressed confidence in receiving cash in-flows in the very short term to cover the Company's immediate cash requirements. At this point, although the Company has received some additional funding, the cash in-flows contemplated in that announcement have not yet been received. However, the Directors remain confident of securing additional cash in-flows in the near future. The Directors will keep the market informed of developments. 19th February 2004 ENQUIRIES: GeneMedix plc Tel: 01638 663 320 Julian Attfield, Chief Financial Officer Bankside Consultants Tel: 0207 444 4140 Michael Padley/Susan Scott Further copies of this announcement are available from the Group's head office - Rosalind Franklin House, Fordham Road, Newmarket, Suffolk, CB8 7XN |
Posted at 19/2/2004 10:12 by baker man This appears to be the reason for the lead in AsiaTalks with MNC set ablaze demand for GeneMedix February 19th By SERENA NG (SINGAPORE) The Singapore market's only pure biotechnology stock, GeneMedix plc, yesterday gave an inkling of the huge potential new developments that the pharmaceutical industry could bring when its shares shot up two-thirds in a single day on hopes of a merger with a US giant. GeneMedix's shares, which had already gained nearly 30 per cent on Tuesday to 56 cents, yesterday jumped to a two-year high of $1.12 in intraday trade before ending at 92 cents, up 36 cents or a hefty 64 per cent. Some 31.3 million of GeneMedix shares were traded yesterday. The two-day share surge boosted GeneMedix's market capitalisation to some $275 million, from just $130 million on Monday. Investor euphoria over the counter was attributable to a Monday announcement by the London and Singapore-listed drugmaker, which had revealed that a 'significant transaction' was being negotiated with an international pharmaceutical products company. Loss-making GeneMedix, which was responding to recent market speculation, also said the talks 'may or may not lead to a merger between the two companies', adding it had recently indicated it was looking to access the US markets. Last week, the UK-based biotech firm also announced that it is working with the Bank of New York to establish an American Depository Receipt Programme on Nasdaq. GeneMedix cited its interest in accessing the US capital markets, which it said have tremendous interest in the emerging field of biogenerics, or generic therapeutic products that are produced through modern biotechnology processes. While GeneMedix, which makes protein-based drugs, did not name the company it is in talks with, market players concluded that the potential partner was probably an American firm with a sizeable presence. Bloomberg News also quoted the group's chief financial officer Julian Attfield saying that the talks, though preliminary, are focused on forming a collaborative partnership rather than a takeover by a potential buyer. GeneMedix's London-listed shares, meanwhile, have also more than doubled since the start of this week. The company was listed in Singapore on Dec 1, 2000, one day after listing on London, and its initial public offering (IPO) shares had been priced at 90 pence or $2.22. The stock subsequently hit a high of $3.06 here in February 2001, while its record low of 31.5 cents was seen earlier this month on Feb 2. Amid yesterday's stunning share price surge, some market players in Singapore reacted with scepticism. Said one active trader: 'It's a ridiculous price, and my gut feeling is that it's all hyped up. I did not like the fact that the stock ran up for a few days and then the company made its announcement.' He added that the sharp run-up might lead the other party to pull out, especially if a share swap was being planned. But for other market watchers, the volatility of GeneMedix's shares was seen as a reflection of the high risk-to-reward factor of biotechnology stocks, as such companies tend to be mired in losses for years before getting a big break. GeneMedix reported a net loss of 4.8 million (S$15 million) for the nine months to August 2003, versus a net loss of 6.6 million a year ago. In 2002, a local biotechnology start-up, Rockeby Biomed, was turned away by the Singapore Exchange because of concerns that the company could not turn profitable within 12 months. Rockeby, which is managed by mainly Singaporeans, successfully listed in Australia at the end of 2003 after raising A$4 million (S$5.3 million) in an IPO at 20 Australian cents each. Its shares yesterday ended at 18.5 Australian cents |
Posted at 16/2/2004 12:59 by baker man techair - lolLooking at a possible figure to put on gmx share price, i would expect nothing less than 16.5p as this was the level at which they raised funds in November - The private investors who put the money up (& are part of their ongoing Penang operations)would not be happy at anything less. |
Posted at 09/2/2004 23:14 by anakin54321 A quick glance at the shareprice history will reveal that the market recovery of the last 10 months or so has had no discernable impact on this share. Currently though it does appear to have stabilised at around the 9 pence mark (it rose significantly today on modest volume) which values GMX at around £27m.Anyone remotely interested should listen to the Wall Street Reporter interview with the CEO a few weeks ago ( www.wallstreetreport With the fourth quarter results due on the 26th of this month (according to the website) we could well see a gradual increase over the next couple of weeks in anticipation of more corporate developments.If GMX can make inroads into the US market than its potential will be rapidly realised. After all, it will only take a relatively modest share of a market valued in the tens of billions to transform the share price. All IMHO. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
